View Exam | PowerPak

1. Which 2 conditions are together referred to as invasive pneumococcal disease?

A. Bacteremia and meningitis B. Sinusitis and pneumonia C. All-cause pneumonia and influenza D. Otitis media and chronic obstructive pulmonary disease E. Respiratory syncytial virus and community-acquired pneumonia

2. Invasive pneumococcal disease is most likely to affect which age group?

A. Age 5 years and younger B. Age 5 to 17 years C. Age 18 to 34 years D. Age 35 to 49 years E. Age 50 years and older

3. The major burden of disease caused by Streptococcus pneumoniae is due to what condition?

A. Asplenia B. Community-acquired pneumonia C. Nursing-home acquired pneumonia D. Congestive heart failure E. Cerebrospinal fluid leaks

4. What proportion of nursing home patients is readmitted to the hospital following discharge for pneumococcal pneumonia?

A. 5% B. 10% C. 30% D. 45% E. 75%

5. The pneumococcal polysaccharide vaccine evokes what type of immune response?

A. A serotype-specific, T-cell-independent response B. A serotype-specific, T-cell-dependent response C. A serotype-nonspecific, T-cell-independent response D. A serotype-nonspecific, T-cell-dependent response E. An IgA-specific response

6. According to the Advisory Committee on Immunization Practices, which of the following pneumococcal vaccines currently licensed in the United States should be administered to immunocompetent individuals aged 65 years or older?

A. 7-valent pneumococcal conjugate vaccine (PCV7) B. 13-valent pneumococcal conjugate vaccine (PCV13) C. 23-valent pneumococcal polysaccharide vaccine (PPSV23) D. All of the above E. B & C

7. When administering pneumococcal vaccines to immunocompromised adult patients aged 19 years or older, what is the minimum interval for vaccinating when 13-valent pneumococcal conjugate vaccine (PCV13) is given first and 23-valent pneumococcal polysaccharide vaccine (PPSV23) is given second?

A. 4 weeks B. 8 weeks C. 3 months D. 6 months E. 12 months

8. Data on the use of pneumococcal vaccines in patients 65 years of age or older indicate that:

A. Administering 23-valent pneumococcal polysaccharide vaccine (PPSV23) every 5 years through the end of life improves vaccine efficacy B. Administering 13-valent pneumococcal conjugate vaccine (PCV13) followed 1 year later by PPSV23 provides broad protection C. For an immunocompromised patient, PCV13 should be given every 5 years D. For a vaccine-naïve patient, PPSV23 should be administered first, followed 1 year later by PCV13 E. Pneumococcal vaccines are relatively ineffective in this population and should be considered optional

9. Which of the following statements regarding the Centers for Medicare and Medicaid Services (CMS) is TRUE as it relates to pneumococcal vaccines?

A. CMS pays for pneumococcal vaccines under Medicare Part D B. CMS requires long-term care (LTC) facilities to offer pneumococcal vaccine to all residents C. CMS does not allow pharmacies to bill for pneumococcal vaccines apart from bundled billing in the LTC facility D. CMS pays for both pneumococcal vaccines and their administration prospectively, even if the patient refuses the vaccines E. CMS does not allow standing orders to be used for pneumococcal vaccines

10. While there is some state-to-state variability, in general, all immunization information systems allow for:

A. Timely billing of vaccines and their administration B. Consistent remuneration for vaccines regardless of provider type C. Documentation of immunization events D. Tracking of facility vaccine inventories E. Recording and reporting serious vaccine adverse events

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which 2 conditions are together referred to as invasive pneumococcal disease?

2. Invasive pneumococcal disease is most likely to affect which age group?

3. The major burden of disease caused by Streptococcus pneumoniae is due to what condition?

4. What proportion of nursing home patients is readmitted to the hospital following discharge for pneumococcal pneumonia?

5. The pneumococcal polysaccharide vaccine evokes what type of immune response?

6. According to the Advisory Committee on Immunization Practices, which of the following pneumococcal vaccines currently licensed in the United States should be administered to immunocompetent individuals aged 65 years or older?

7. When administering pneumococcal vaccines to immunocompromised adult patients aged 19 years or older, what is the minimum interval for vaccinating when 13-valent pneumococcal conjugate vaccine (PCV13) is given first and 23-valent pneumococcal polysaccharide vaccine (PPSV23) is given second?

8. Data on the use of pneumococcal vaccines in patients 65 years of age or older indicate that:

9. Which of the following statements regarding the Centers for Medicare and Medicaid Services (CMS) is TRUE as it relates to pneumococcal vaccines?

10. While there is some state-to-state variability, in general, all immunization information systems allow for:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which 2 conditions are together referred to as invasive pneumococcal disease?

2. Invasive pneumococcal disease is most likely to affect which age group?

3. The major burden of disease caused by Streptococcus pneumoniae is due to what condition?

4. What proportion of nursing home patients is readmitted to the hospital following discharge for pneumococcal pneumonia?

5. The pneumococcal polysaccharide vaccine evokes what type of immune response?

6. According to the Advisory Committee on Immunization Practices, which of the following pneumococcal vaccines currently licensed in the United States should be administered to immunocompetent individuals aged 65 years or older?

7. When administering pneumococcal vaccines to immunocompromised adult patients aged 19 years or older, what is the minimum interval for vaccinating when 13-valent pneumococcal conjugate vaccine (PCV13) is given first and 23-valent pneumococcal polysaccharide vaccine (PPSV23) is given second?

8. Data on the use of pneumococcal vaccines in patients 65 years of age or older indicate that:

9. Which of the following statements regarding the Centers for Medicare and Medicaid Services (CMS) is TRUE as it relates to pneumococcal vaccines?

10. While there is some state-to-state variability, in general, all immunization information systems allow for:

« Return to Activity

Customers who Purchased
this Activity also Purchased